These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 9309542

  • 1. 111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients.
    Legovini P, De Menis E, Billeci D, Conti B, Zoli P, Conte N.
    J Endocrinol Invest; 1997; 20(7):424-8. PubMed ID: 9309542
    [Abstract] [Full Text] [Related]

  • 2. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U, Reichel M, Fett U, Saeger W, Quabbe HJ.
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [Abstract] [Full Text] [Related]

  • 3. [Prediction of pharmacological effect of octreotide in acromegaly by means of 111In-pentetreotide scintigraphy and calculation of a pituitary uptake index].
    Görges R, Cordes U, Engelbach M, Bartelt KM, Haberern G, Hey O, Beyer J, Bockisch A.
    Nuklearmedizin; 1997 Jun; 36(4):117-24. PubMed ID: 9289697
    [Abstract] [Full Text] [Related]

  • 4. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
    Plöckinger U, Bäder M, Hopfenmüller W, Saeger W, Quabbe HJ.
    Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
    [Abstract] [Full Text] [Related]

  • 5. Prediction of efficacy of octreotide therapy in patients with acromegaly.
    Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Sarno A, Longobardi S, Merola B, Salvatore M, Lombardi G.
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2356-62. PubMed ID: 8964877
    [Abstract] [Full Text] [Related]

  • 6. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide.
    Broson-Chazot F, Houzard C, Ajzenberg C, Nocaudie M, Duet M, Mundler O, Marchandise X, Epelbaum J, Gomez De Alzaga M, Schäfer J, Meyerhof W, Sassolas G, Warnet A.
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):589-98. PubMed ID: 9425399
    [Abstract] [Full Text] [Related]

  • 7. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.
    Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H, Stevenaert A, Chanson P, Beckers A.
    Eur J Endocrinol; 2005 Jan; 152(1):61-6. PubMed ID: 15762188
    [Abstract] [Full Text] [Related]

  • 8. Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: correlation with the effect of a single administration of octreotide on serum TSH levels.
    Losa M, Magnani P, Mortini P, Persani L, Acerno S, Giugni E, Songini C, Fazio F, Beck-Peccoz P, Giovanelli M.
    Eur J Nucl Med; 1997 Jul; 24(7):728-31. PubMed ID: 9211757
    [Abstract] [Full Text] [Related]

  • 9. Octreotide as primary therapy for acromegaly.
    Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL.
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [Abstract] [Full Text] [Related]

  • 10. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
    Boni G, Ferdeghini M, Bellina CR, Matteucci F, Castro Lopez E, Parenti G, Canapicchi R, Bianchi R.
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
    [Abstract] [Full Text] [Related]

  • 11. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
    Cremonini N, Furno A, Sforza A, Chiarini V, Graziano E, Zampa G, Turba E.
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
    [Abstract] [Full Text] [Related]

  • 12. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
    Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa W, Salvatore M, Lombardi G.
    J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
    [Abstract] [Full Text] [Related]

  • 13. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3.
    Casarini AP, Pinto EM, Jallad RS, Giorgi RR, Giannella-Neto D, Bronstein MD.
    J Endocrinol Invest; 2006 Oct; 29(9):826-30. PubMed ID: 17114915
    [Abstract] [Full Text] [Related]

  • 14. Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors.
    Oppizzi G, Cozzi R, Dallabonzana D, Orlandi P, Benini Z, Petroncini M, Attanasio R, Milella M, Banfi G, Possa M.
    J Endocrinol Invest; 1998 Sep; 21(8):512-9. PubMed ID: 9801992
    [Abstract] [Full Text] [Related]

  • 15. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
    Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G, Cozzi R.
    J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
    [Abstract] [Full Text] [Related]

  • 16. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
    Ferone D, Pivonello R, Lastoria S, Faggiano A, Del Basso de Caro ML, Cappabianca P, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
    [Abstract] [Full Text] [Related]

  • 17. Somatostatin receptor scintigraphy in pituitary adenomas: a somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo.
    Duet M, Ajzenberg C, Benelhadj S, Lajeunie E, Lormeau B, Guillausseau PJ, Rohmer V, Vilain D, Mundler O, Warnet A.
    J Nucl Med; 1999 Aug; 40(8):1252-6. PubMed ID: 10450674
    [Abstract] [Full Text] [Related]

  • 18. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G, Angelopoulos NG, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Protonotariou A, Lytras A.
    Neuroendocrinology; 2006 Aug; 83(3-4):249-57. PubMed ID: 17047390
    [Abstract] [Full Text] [Related]

  • 19. [Somatostatin analogs in the clinical management of pituitary neoplasms].
    Colao A, Dorato M, Pulcrano M, Rossi FW, Auriemma RS, Lombardi G, Lastoria S.
    Minerva Endocrinol; 2001 Sep; 26(3):181-91. PubMed ID: 11753242
    [Abstract] [Full Text] [Related]

  • 20. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.
    Shi W, Buchanan KD, Johnston CF, Larkin C, Ong YL, Ferguson R, Laird J.
    Clin Endocrinol (Oxf); 1998 Mar; 48(3):303-9. PubMed ID: 9578820
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.